Pfizer, Teva running short on antibiotic azithromycin amid COVID-19 therapy hunt

In the hunt for a COVID-19 therapy, some researchers have hit upon a combination of antimalarial hydroxychloroquine and antibiotic azithromycin as a potential answer. So far, clinical results have been mixed at best—but demand for azithromycin has still been sky-high, and drugmakers are feeling the pinch.